Recent news on Zanaflex

Acorda Therapeutics to Present at Friedman, Billings, Ramsey & Co ...  -  May 24, 2007
PharmaLive.com (press release),The Company's marketed products include Zanaflex CapsulesTM (tizanidine hydrochloride), a short-acting drug for the management of spasticity.

Best canadian and usa pharmacies online resourse  -  May 4, 2007
Journal lycéen,Some are involved in research for pharmaceutical zanaflex manufacturers, developing new drugs and tenuate therapies and testing their effects on people.

Acorda Therapeutics to Host Analyst and Investor Reception  -  Apr 25, 2007
Business Wire (press release),The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity.

FDA MedWatch: Zanaflex (tizanidine hydrochloride) Tablets and ...  -  Apr 12, 2007
PharmaLive.com (press release),Reference is made to the February 5,2007 email in which the content of the Dear Healthcare Provider letter was approved for Zanaflex capsule (tizanidine

Revised Product Labeling for Zanaflex  -  Apr 13, 2007
Facts and Comparisons,Acorda Therapeutics has revised product labeling (Contraindications and Warnings sections) for Zanaflex (tizanidine), indicated for the treatment of

Acorda Therapeutics to Present at 7th Annual Fortis Biotech Conference  -  Apr 18, 2007
PharmaLive.com (press release),The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity.

Prescribers Warned of Tizanidine Drug Interactions  -  Apr 13, 2007
Medscape (subscription)April 13, 2007 — Concomitant use of fluvoxamine or ciprofloxacin with tizanidine HCl (Zanaflex capsules and tablets, Accorda Therapeutics) is

Acorda Tackles Multiple Sclerosis  -  Mar 30, 2007
BusinessWeekZanaflex treats spasticity or muscular spasm, a condition associated with multiple sclerosis. Acorda's newer product is Fampridine-sr, which alleviates

Zacks Bull and Bear of the Day Highlights: Amphenol Corporation ...  -  Apr 13, 2007
Business Wire (press release),The company has one major product currently approved for sale with Zanaflex, and one major candidate in late-stage clinical trials with Fampridine-SR.

Police Reports - Munfordville man killed in single-car crash in ...  -  Apr 12, 2007
Bowling Green Daily News,Also in the room were digital scales, a metal pipe with marijuana residue and a bottle containing Zanaflex pills, all of which belonged to Thompson,

Plenty of pharma companies call Hudson Valley 'home'  -  27 Mar 2007
Remote Access,Acorda markets a drug called Zanaflex that helps patients with multiple sclerosis and spinal-column injuries to manage spasticity, an inability to initiate

Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data ...  -  Mar 19, 2007
PharmaLive.com (press release),The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity.

Acorda Therapeutics Reports Fourth Quarter and Full Year 2006 ...  -  Feb 20, 2007
PharmaLive.com (press release),In addition, sales of Zanaflex Capsules grew strongly in 2006, and we completed our second expansion of our sales force to 65 professionals.

Acorda Shares Fall After Downgrade  -  Feb 21, 2007
Forbes,The Hawthorne, NY-based company on Tuesday reported a narrower fourth-quarter loss, as sales of Zanaflex muscle relaxant tablets and caplets surged to $8.2

Eye on Acorda Therapeutics  -  Feb 20, 2007
Seeking Alpha,Zanaflex is a short-acting marketed drug for the management of spasticity, or pain and weakness associated with MS and other diseases.

Acorda Therapeutics "buy," target price raised  -  Feb 22, 2007
newratings.com...the analysts mention that the company has reported its 4Q loss per share below the estimates on account of higher-than-anticipated Zanaflex sales.

Acorda Therapeutics Narrows 4Q Loss  -  Feb 20, 2007
Forbes,Acorda Therapeutics said combined gross sales of its Zanaflex tablets and capsules reached $8.2 million, compared with $2.7 million during the same quarter

Hawthorne-based Acorda Therapeutics reports smaller loss  -  Feb 20, 2007
Business in the Burbs,Acorda also reported strong sales of Zanaflex capsules, a short-acting drug used in the treatment of spasticity, a disorder in which muscles are

Acorda Therapeutics to Host Conference Call to Report Fourth ...  -  Feb 13, 2007
PharmaLive.com (press release),The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity.

Hawthorne-based Acorda receives second $5M payment  -  Feb 7, 2007
Business in the Burbs,The agreement called for the company to receive $10 million to increase the staff of people selling Zanaflex Capsules from 32 to 65.

Market Report -- In Play (ACOR)  -  Feb 7, 2007
MSN Money...of Paul Capital Healthcare to receive a total of $10 mln to fund the expansion of its Zanaflex Capsules salesforce from 32 to 65 professionals.

Pre-Market Stock Notes (FEB 7, 2007)  -  Feb 7, 2007
24/7 Wall St.,...(ACOR) Acorda Therapeutics receives additional $5 million from Paul Capital Healthcare to fund the expansion of its Zanaflex.

IBM executive is black engineer of the year  -  Feb 8, 2007
White Plains Journal News,The agreement called for the company to receive $10 million to increase the staff selling Zanaflex capsules from 32 to 65. The company received the payment

Acorda Therapeutics Announces Completion of Zanaflex Capsules ...  -  Jan 8, 2007
PharmaLive.com (press release),For 2005, Acorda reported shipments of Zanaflex Capsules and Zanaflex tablets to wholesalers of $18.6 million, using its pilot sales force of 14

Acorda Therapeutics Elects Barry Greene, COO of Alnylam, to its ...  -  Jan 8, 2007
PharmaLive.com (press release),The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity.

CARISOPRODOL , carisoprodol use , order soma carisoprodol  -  Dec 27, 2006
Indymedia Colombia,Although the carisoprodol the ve here's zanaflex with. To the carisoprodol of types of carisoprodol and can increase unwanted side effects may occur that

Acorda Therapeutics to Receive Up to $10 Million from Paul Capital ...  -  Nov 29, 2006
PharmaLive.com (press release),The Company previously received $15 million to fund the initial expansion of its salesforce from 14 to 32 professionals, as well as other Zanaflex Capsules

Acorda Therapeutics Provides Update on Clinical Development of ...  -  Dec 8, 2006
PharmaLive.com (press release),The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity.

The Deadly Side Effects of Net Pharmacies  -  Dec 10, 2006
BusinessWeekAmong them: antidepressants Zoloft and Paxil, muscle relaxant Zanaflex, and weight-loss drugs Meridia and Bontril. In a June, 2006, report for Columbia's

Atlas Air values 20-year agreement with DHL at up to $3.5B  -  Nov 30, 2006
The Journal News.com,The proceeds will fund a previously announced sales force expansion from 32 to 65 and promotional programs for Zanaflex Capsules, a short-acting drug used

Acorda Therapeutics To Expand Zanaflex Capsules Sales Force To 65 ...  Oct 17, 2006
The Acorda sales team promotes Zanaflex Capsules. The current sales force of 32 people currently reaches approximately 3,200 specialists. ... -Trading Markets, Acorda Therapeutics Announces Expansion of Zanaflex Capsules(TM) ...  Oct 17, 2006
...high-volume prescribers. The Acorda sales team promotes Zanaflex Capsules(TM) (tizanidine hydrochloride). "This second expansion ... -Genetic Engineering News (press release), Acorda Therapeutics Reports Third Quarter 2006 Financial Results  Nov 2, 2006
For the quarter ended September 30, 2006, gross sales of Zanaflex Capsules(TM) (tizanidine hydrochloride) were $5.0 million and gross sales of Zanaflex(R ... -Genetic Engineering News (press release), Acorda Therapeutics Net Loss Declines As Sales Increases - Update  Nov 2, 2006
For the quarter ended September 30, 2006, gross sales of Zanaflex Capsules were $5.0 million and gross sales of Zanaflex tablets were $1.5 million providing ... -Trading Markets, Acorda's Wild Ride  Nov 3, 2006
...quarter. Gross sales of its one marketed drug, Zanaflex, were $6.5 million, with gross margins considerably greater than 70%. The ... -Motley Fool NovaDel Pharma: Promising New Technology Makes It a Buy  Nov 6, 2006
Zanaflex - Tizanidine spray for plasticity, and is currently in pre-clinical characterization. Zanaflex is a trademark of Acorda Therapeutics (ACOR). ... -Seeking Alpha, Acorda Narrows 3Q Net Loss  Nov 2, 2006
Therapeutics Inc. said Thursday its third-quarter net loss narrowed as sales of its Zanaflex muscle relaxants grew. The quarter's ... -Houston Chronicle, Acorda Therapeutics (ACOR) Reports Q3 Loss, Comments on Fampridine ...  Nov 2, 2006
We also have had continued growth in our Zanaflex Capsules franchise, and recently announced the expansion of our commercial sales force from 32 to 65. ... -StreetInsider.com (subscription), Banc of America Starts Acorda Therapeutics (ACOR) at Buy  Nov 2, 2006
...disorders. The Company's marketed products include Zanaflex Capsules, a short-acting drug indicated for the management of spasticity. ... -StreetInsider.com (subscription), Rodman & Renshaw Healthcare Conference 2006 Presenter Profiles  Nov 3, 2006
Acorda’s marketed products include Zanaflex CapsulesTM (tizanidine hydrochloride) and Zanaflex® (tizanidine hydrochloride) tablets. ... -Business Wire (press release), Market Report -- In Play (ACOR)  Oct 17, 2006
Acorda Therapeutics announces expansion of Zanaflex Capsules sales force to 65 Co announces that it will expand its sales force to 65 people, including 52 area ... -MSN Money Acorda Therapeutics to Host Conference Call to Report Third ...  Oct 26, 2006
...that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of ... -Business Wire (press release), Market Report -- Short Stories (ACOR)  Oct 24, 2006
...tgt on ACOR to $25 from $14 based on positive comments from experts on potential market, expanded sales force, strong execution with Zanaflex suggest further ... -MSN Money Acorda (ACOR) Expands Sales Force to 65  Oct 17, 2006
...physicians who are high-volume prescribers. The Acorda sales team promotes Zanaflex Capsules. John Librie, VP, Sales and Marketing ... -StreetInsider.com (subscription), Foro de Shell Security - Seguridad informática  Oct 27, 2006
...logy. For intermediate-grade lymphomas, CHOP chemothe zanaflex apy remains the standard of care at this time. Ap zantac ospec. respo ... -Shell Security, Burbs: Hawthorne-based Acorda Therapeutics to double work force  Oct 18, 2006
...prescribers. The Acorda sales force will promote Zanaflex Capsules, a short-acting drug used in the treatment of spasticity. Acorda ... -The Journal News.com, Acorda Therapeutics to Present at the BioCentury Newsmakers in the ...  Aug 31, 2006
...that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules , the risk of ... -Business Wire

Acorda Therapeutics Provides Update on Clinical Development of ...  -  Dec 8, 2006
PharmaLive.com (press release),The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity.

Acorda Therapeutics to Receive Up to $10 Million from Paul Capital ...  -  Nov 29, 2006
PharmaLive.com (press release),The Company previously received $15 million to fund the initial expansion of its salesforce from 14 to 32 professionals, as well as other Zanaflex Capsules

The Deadly Side Effects of Net Pharmacies  -  Dec 10, 2006
BusinessWeekAmong them: antidepressants Zoloft and Paxil, muscle relaxant Zanaflex, and weight-loss drugs Meridia and Bontril. In a June, 2006, report for Columbia's

Atlas Air values 20-year agreement with DHL at up to $3.5B  -  Nov 30, 2006
The Journal News.com,The proceeds will fund a previously announced sales force expansion from 32 to 65 and promotional programs for Zanaflex Capsules, a short-acting drug used

Acorda Therapeutics Reports Second Quarter 2006 Financial Results  Aug 3, 2006
For the quarter ended June 30, 2006, gross sales were $3.9 million for Zanaflex Capsules(TM) (tizanidine hydrochloride) and $4.0 million for Zanaflex(R ... -International News Service

Acorda Therapeutics to Host Conference Call to Report Second ...  Jul 27, 2006
...that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of ... -Genetic Engineering News

Burbs: IBM buys MRO for $740M  Aug 4, 2006
For the quarter, Acorda reported revenues for its sole product, Zanaflex, rose to $7.9 million, up from $478,000 a year ago. Regeneron Pharmaceuticals Inc. ... -The Journal News.com

Former county health official disciplined  Jul 9, 2006
After prescribing Methadone, Ultram, Celebrex and Zanaflex along with Hydrocone and Tramdol, Arredono prescribed Mondenafil as a sedation drug for the patient ... -Waxahachie Daily Light

Acorda Therapeutics to Host Analyst and Investor Day  Jul 6, 2006
...that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules , the risk of ... -Genetic Engineering News



Acorda Therapeutics Reports First Quarter 2006 Financial Results  May 5, 2006
For the quarter ended March 31, 2006, gross sales of Zanaflex Capsules(TM) (tizanidine hydrochloride) were $2.3 million and gross sales of Zanaflex(R) tablets ... - Genetic Engineering News

Acorda Therapeutics Reports First Quarter 2006 Financial Results  May 5, 2006
For the quarter ended March 31, 2006, gross sales of ZanaflexCapsules(TM) (tizanidine hydrochloride) were $2.3 million and grosssales of Zanaflex(R) tablets ... - Finanzen.net

Acorda Therapeutics Q1 Net Loss Narrows - Update  May 5, 2006
The gross sales included $2.3 million through the sale of Zanaflex Capsules and $1.6 million resulting from the sale of Zanaflex tablets. ... - Trading Markets

Acorda Q1 Loss Widens - Quick Facts  May 5, 2006
For the first quarter gross sales of Zanaflex Capsules were $2.3 million and gross sales of Zanaflex tablets were $1.6 million, resulting in a combined gross ... - Trading Markets

Ask the Clinician: Answers to Readers' Questions  May 8, 2006
...migraines, and just good old fashioned headaches. My Dr. has prescribed Maxalt and Zanaflex. I also must take daily pain meds (Vicodin ... - About - News & Issues

Acorda Therapeutics to Host Conference Call to Report First ...  Apr 28, 2006
...that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of ... - Genetic Engineering News

Living with a Brain Disorder: Debbie, 31-35, Chronic Fatigue ...  May 6, 2006
...when I ask them to explain. One drug, Zanaflex, caused by BP to drop to 60/40 and pulse to 40. This happened for months the doc ... - GNIF Brain Blogger





Acorda Therapeutics Reports Fourth Quarter and Full Year 2005 ...  Mar 31, 2006
31, 2005. "The launch of Zanaflex Capsules in April 2005 transformed Acorda into a fully-integrated biotechnology company. In 2005 ... - Genetic Engineering News

Acorda Therapeutics Announces Exercise of Over-Allotment Option by ...  Mar 13, 2006
...that could cause actual results to differ materially, including Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of ... - Genetic Engineering News

Acorda Therapeutics, Inc. [ACOR] President & CEO to Ring The ...  Apr 6, 2006
The Company's marketed products include Zanaflex Capsules (tizanidine hydrochloride), a short-acting drug indicated for the management of spasticity. ... - Market Wire

Kelly pleads guilty in fatal DUI case  Mar 29, 2006
Monroe County Jailer Chase Brown said he found Kelly in possession of several prescription drugs, including lithium carb, zanaflex, zantac and vitaril ... - Monroe County Advocate Democrat

Big paydays ahead for Sound Federal execs  Apr 1, 2006
The company began marketing its first product, Zanaflex capsules and tablets for spasticity, about a year ago. Four top executives at Pepsi Bottling Group Inc. ... - The Journal News.com

'Of course we made mistakes'  Mar 8, 2006
...after problems with its Alzheimer's Disease treatment, the market severely criticised its accounting policies and one of its leading drugs, Zanaflex, lost its ... - Unison.ie



Acorda Therapeutics(R) Announces Completion of Enrollment in ...  Mar 3, 2006
Acorda also announced that it has expanded its in-house, specialty sales force for Zanaflex Capsules(TM) (tizanidine hydrochloride) from 14 to 32. ... - Genetic Engineering News,

Acorda Therapeutics Invites Investors to the SG Cowen & Co. 26th ...  Mar 1, 2006
...the central nervous system. Acorda currently markets Zanaflex Capsules for the management of spasticity. The Company's lead product ... - Genetic Engineering News,

Acorda plans public offering  Feb 7, 2006
The company, which lost $26 million the first nine months of 2005 and does not expect to make a profit for several years, markets Zanaflex capsules, a drug ... - The Journal News.com,

Burbs: Acorda Therapeutics becomes a public company  Feb 11, 2006
It markets Zanaflex Capsules for the management of muscle spasms, and is in a Phase 3 clinical trial for a drug to help people with multiple sclerosis walk. ... - The Journal News.com,

Paul Royalty Fund Purchases Revenue Interest in Acorda's Zanaflex ...  Jan 19, 2006
19 /PRNewswire/ -- Paul Royalty Fund today announced that an affiliate of the fund has purchased a portion of the future net revenues in Zanaflex Capsules(TM ... - Yahoo! News

Acorda plans public offering  Feb 7, 2006
The company, which lost $26 million the first nine months of 2005 and does not expect to make a profit for several years, markets Zanaflex capsules, a drug ... - The Journal News.com

Elan meldt financiële resultaten vierde kwartaal en hele jaar ...  Jan 31, 2006
27.8 34.7 2.7 3.2 Skelaxin(TM) 12.2 17.9 3.5 2.7 Ritalin(TM) 11.8 13.8 4.9 4.3 Avinza(TM) 15.8 13.4 4.1 5.8 Diltiazem(TM) 19.3 18.6 - 4.0 Zanaflex(TM) - 11.1 ... - Netherlands Corporate News (persbericht)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional